Biography:

Dr. Rishat Abbas Borhan - “ Richat Abbas ”         

• PhD, September 1994, in Pharmaceutical Sciences (Pharmacokinetics and Drug Metabolism),  Division of Pharmaceutics and Pharmaceutical Chemistry, Graduate School of Pharmacy, The Ohio State University, Columbus, Ohio, 1990 to 1994. Dissertation title: “Theoretical Development and Experimental Validation of Physiologically Based Pharmacokinetic and Pharmacodynamic Models for Inhibition of Acetylcholinesterase”.  From 1989 to 1990, Graduate Program, College of Pharmacy, Washington State University, Pullman, Washington. 
• Post-Doctoral Research, 1994 to 1996, title: “development and validation of physiologically based pharmacokinetic models to describe uptake, distribution, metabolism, and excretion of trichloroethylene and its metabolites (chloral hydrate, trichloroethanol, trichloroethanol glucuronide, trichloroacetic acid and  dichloroacetic acid), and extrapolate animal pharmacokinetics/toxicokinetics to humans. Toxicology Division, Armstrong Laboratory/Geo-Centers, Wright-Patterson Air Force Base, Dayton, Ohio.
• Pharmacokineticist, Senior Pharmacokineticis/Manager, PK/PD, Drug Metabolism and Safety Evaluation, Otsuka America Pharmaceutical, Inc., from 1996 to 2000. Rockville, Maryland. Participated in research and development of new drugs for treatment of cardiovascular and CNS diseases. Contributed to the development of  AbilifyÒ (aripiprazole, A CNS drug for treatment of Schizophrenia) and PLETALÒ (cilostazol, a cardiovascular drug for treatment of Intermittent Claudication).   

Staff Scientist/Director, Biopharmaceutics, Emisphere Technologies, Inc. Tarrytown, New York, 2000 - 2002.  Conducted preclinical and clinical pharmacokinetic, drug metabolism and pharmacodynamic research and contributed to the development of oral insulin for diabetes, oral heparin for cardiovascular diseases, and oral cromolyn for asthma.  Designed, conducted, and analyzed oral insulin and oral cromolyn first-in-man clinical trials, and initial evaluation of oral insulin in type II diabetic patients. Applied for United States Patents for “Oral Insulin Therapy” and for “Formulations for Oral administration of Cromolyn Sodium”.

• Associate Clinical Director/Clinical Pharmacologist, Department of Clinical Pharmacology, Global Drug Development, Hoffmann-La Roche Inc., a global research-driven major pharmaceutical and diagnostic company, Nutley, New Jersey, 2002 to 2004. Conducted clinical pharmacokinetic/pharmacodynamic and drug metabolism research and contributed to the development of anti-cancer (Tarceva^TM – an oral noncytotoxic drug for treatment of locally advanced or metastatic lung cancer ), diabetes (for type II diabetes) and asthma drugs.
• Director/Lead Investigator, Department of Clinical Pharmacology, Translational Medicine, Global Drug Research and Development, Wyeth Research, 2004 to present.  Responsible for conducting clinical pharmacokinetic and pharmacodynamic research, and development of anti-cancer drugs for various tumors (breast cancer, lung cancer, colorectal cancer, pancreatic cancer, melanoma, head and neck cancer, ovarian cancer, and chronic myelogenous leukemia).  Wyeth Research (Collegeville, Pennsylvania), a division of Wyeth, has leading products and R&D in the areas of women’s health care, cardiovascular disease, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines and nutritional products. Wyeth is one of the world’s largest research-driven major pharmaceutical and health care companies.

AWARDS:

1) “Best Abstract” - Pharmacokinetics of Human Insulin Delivered Orally in Healthy    Volunteers – Presented at the Diabetes Technologies Meeting, Nov. 2-3, 2001.  San Francisco, CA.

2) “Best Paper in the Field of Risk Assessment”, titled “A Physiologically Based Pharmacokinetic Model for Trichloroethylene and its Metabolites, Chloral Hydrate, Trichloroacetate, Dichloroacetate, Trichloroethanol, and Trichloroethanol Glucuronide” by Society of Toxicology.  (Toxicol. Appl. Pharm.  127, 15-30, 1997). 1999, New Orleans, LA

3) “Science and Technology Achievement Award” by U.S. Department of Defense - Air Force Material Command - May 1996.          

4) “Scientific Achievement Award” by Department of the Air Force, research paper titled “Formation of Dichloroacetic Acid by Rat and Mouse Gut Microflora, an In Vitro Study”. Biochemical and Biophysical Research Communications, 228, 639-645, Nov.1996.

5) “Graduate Research Assistant Award” 1990 to 1994, The Ohio State University, Columbus, Ohio. 

Publications:

1. R Abbas, Y Hijazi, JP Tang, LM Renzetti, A Rames and H Welker^.  Effect of R411, a Dual a4/b1-a4/b7 Integrin Antagonist Being Developed for Asthma, on the Activities of the Major Drug Metabolizing Enzymes After Oral Administration in Healthy Subjects.  Clinical Pharmacology & Therapeutics, Vol. 75, No.2, p-79, 2004.
2. Kidron M.; Dinh S.; Menachem Y.; Abbas R.; Variano B.; Goldberg M.; Arbit E.; Bar-On H. A novel per-oral insulin formulation: proof of concept study in non-diabetic subjects   Diabetic Medicine, April 2004, vol. 21, no. 4, pp. 354-357(4)

3. Richat Abbas,  Scott Fettner, Myriam Riek, Sunita Bulsara, Michael Pantze, Marta Hamilton, Paul Frohna, and Ashok Rakhit   A drug-drug interaction study to evaluate the effect of rifampicin on the pharmacokinetics of the EGF receptor tyrosine kinase inhibitor, Tarceva^TM, in healthy subjects.   Proc Am Soc Clin Oncol 22: page 137, a-548, 2003
4. Youssef Hijazi, PhD, Horst Welker, PhD, Albert E. Dorr, PhD, Jian-Ping Tang, PhD, Roger Blain, PhD, Louis M. Renzetti, PhD and Richat Abbas, PhD Pharmacokinetics, Pharmacokinetics, Safety, and Tolerability of R411, a Dual {alpha ...
   ... The Journal of Clinical Pharmacology, 2004; 44:1368-1378 © 2004 American
   College of Clinical Pharmacology.
5. C. Kapitza, E. Arbit, R. Abbas, M. Goldberg, M. Hompesch, L. Heinemann, T. Heise, Oral Insulin: Proof of concept in type 2 diabetic patients.  Diabetes. 52-S.1. A37, 2003.
6. Ashok Rakhit, Scott Fettner, Stephen Davis, Richat Abbas, Flavio De Rosa, Ulrich Brennscheidt, Chis Twelves and Jose Baselga.  Lack of pharmacokinetic interaction between erlotinib, docetaxel and capecitabine in breast cancer patients.  European Journal of Cancer, Supplements, Vol. 1, No. 5, p-S115 09. 2003.
7. Richat Abbas, Scott Fettner, Myriam Riek, Stephen Davis, Marta Hamilton, Paul Frohna,. Ashok Rakhit Clinical pharmacokinetics of  erlotinib in healthy subjects. European Journal of Cancer Supplements; Vol. 1, No. 5, p-S168, 09. 2003.
8. Zhongping John Lin, Richat Abbas , Lorraine M. Rusch and Linyee Shum -  Development and Validation of a Sensitive LC-MS/MS Method for the Determination of Cromolyn in Human Plasma, Journal of Chromatography B 788 (2003) 159-166, 2003.
9. Richat Abbas, Andrea Leone-Bay, Rajesh Agawal, Shingai Majuru, Paul Rolan, Cyril Clarke, Colin Scott, Ehud Arbit_­, Robert A. Baughman - Oral Insulin: Pharmacokinetics and Pharmacodynamics of Human Insulin Following Oral Administration of an Insulin/Delivery Agent Capsule in Healthy Volunteers.  Diabetes. Volume 51, A48, S. 2, 2002.

10. Richat Abbas, Robert A. Baughman, S. De Bruyn², Donald Sarubbi, and Ehud Arbit - Oral Cromolyn: Pharmacokinetics of Cromolyn Sodium Delivered Orally in Healthy Volunteers.   Allergy Vol. 57, S73, 338, 2002.
11. Richat Abbas, Rajesh Agarwal, Terry Rivera-Schaub, Andrea Leone-Bay, Kiran Chaudhary, and Robert A. Baughman -  Evaluation of the Effect of Three Different Oral Heparin/SNAC Formulations on Pharmacokinetics (PK) of Heparin Following Oral Administration in Healthy Subjects.  Pharm. Sci Vol. 4, No. 4, R621, 2002.
12. Richat Abbas, A.Chaouki Zerouala, and Robert A. Baughman. Pharmacokinetics (PK) and pharmacodynamics (PD) of SNAd/heparin in  rhesus monkeys. Drug Metabolism Review Vol. 33, 400, 2001.

13.  Richat Abbas, Alda Pombo-Gentile, and Robert A. Baughman.  Absolute bioavailability of SNAD and Pharmacokinetics of SNAD/heparin in rats Drug Metabolism Review Vol. 33, 124, 2001.

14.  Lorraine M. Rusch, Richat Abbas, Catherina M. O’Shaughnessy, Liangfu Chen, and Robert A. Baughman.  Interspecies Comparison of SNAC and SNAD IN VITRO  PLASMA PROTEIN BINDING.  Drug Metabolism Review Vol. 33,  233, 2001.

15.  Catherina M. O’Shaughnessy, Lorraine M. Rusch, Richat Abbas, Liangfu Chen and Robert A. Baughman.  IN VITRO EVALUATION OF SNAC INTERACTION WITH HUMAN CYP450 ISOENZYMES Drug Metabolism Review Vol. 33, 381, 2001.

16.  Richat Abbas, Gregory Osgood, Terry Rivera-Schaub, James C. Kisicki, and Robert A. Baughman.  A Clinical Drug-interaction Study to Evaluate Effect of Antacid Pre-treatment on the Absorption of Heparin and its Delivery Agent, SNAC, Following Oral Administration in Healthy Subjects.  PharmSci  Vol. 3, No. 3, ISSN 1522, 2001.

17.  Richat Abbas, Andrea Leone-Bay, Terry Rivera-Schaub, Shingai Majuru, James C. Kisicki, and Robert A. Baughman.  An Open-label, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of SNAD, an Oral Heparin Delivery Agent, when Administered Orally as SNAD Tablets or Heparin/SNAD Tablets to Healthy Male Volunteers. PharmSci  Vol. 3, No. 3, ISSN 1522-0893, 2001.

18. Abbas, R., Chow, C. P., Browder, N.  J., Thacker, D., Bramer, S. L., Fu, C. H. J., Forbes, W., Odomi, M. and Flockhart, D.A. In vitro Metabolism and Interaction of  Cilostazol  with  Human Hepatic Cytochrome P450 Isoforms. Human & Experimental Toxicology. 19(3). 178-184, 03, 2000.
19. Lash, L. H., Putt, D. A. Brashear, W. T., Abbas, R., Parker, J. C., and Fisher, J. W. Identification of S-(1,2-Dichlorovinyl) glutathione in the blood of human volunteers exposure to trichloroethylene  J. Toxicol Environ. Health 56: 1-21, 1999.
20. Gu, Z., Tata, P. Zhou, D., Abbas, R., Wu, J., Lewis, N. J., and Bramer, S. L.  Sensitive and specific LC-MS/MS method for the analysis of low levels of OPC-29030 and ten metabolites in human plasma and urine. Pharm. Sci.  Suppl. Vol. 1, No. 1,  s-189,  1998.

21.  Abbas, R., Bramer, S. L., Cowart, D., Adeyemo, O. M., Kitani, M., Miyamoto, G., and Browder, N. J.  Interspecies Comparison of TOBORINONE Pharmacokinetics in Rats, Rabbits, Dogs, Monkeys, and Humans. Toxicological Sciences, vol. 42, No.1-S, p216, 1998.

22. Adeyemo, O.M., R. Abbas, D. Sibley, R. Mailman, R. Wilcox, T. Kikuchi, T. Hirose, and N. J. Browder, OPC-14597: Unique pharmacology and receptor binding characterization studies on a novel antipsychotic agent, The Toxicologist, 42, No. 1215, p. 246, 1998
23. Abbas, R., Flockhart, D. A., Thacker, D., Bramer, S. L., Cowart, D.,  and Browder, N. J. In vitro metabolism of toborinone by human liver cytochrome P450 isoforms.  Toxicology Letters, vol. 95, S1, p101, 1998.
24. Fisher, J.W., Mahle, D. and Abbas, R. A Human Physiologically Based Pharmacokinetic Model for Trichloroethylene and its Metabolites, Trichloroacetic Acid and Free Trichloroethanol. Toxicol. Appl. Pharm.  152, 339-359, 1998.

25.  Browder, N. J., Flockhart, D. A., Thacker, D., Bramer, S. L., Cowart, D.,  and Abbas, R. Effect of toborinone on human liver cytochrome P450 isoforms  AND INTERACTION  WITH THEOPHYLLINE. Toxicological Sciences, vol. 42, No.1-S, p91, 1998.

26.  Fu, C. J., Abbas, R., Tata, P. N. V., Cowart, C., Bramer, S. L.  AN HPLC METHOD FOR THE ANALYSIS OF TOBORINONE (OPC-18790) AND FOUR METABOLITES IN HUMAN PLASMA.  Toxicological Sciences, vol. 42, No.1-S, p219, 1998.

27. Abbas, R. Tata, P.  Bramer, S. L.  Li, Y. X. Heitkamp, J.  and Velagaleti, P.  A SENSITIVE AND SPECIFIC CHIRAL HPLC-MS/MS METHOD FOR QUANTITATIVE ANALYSIS OF LOW LEVELS OF R(+) AND S(-) ENANTIOMERS OF OPC-41061 IN HUMAN SERUM. Pharm. Res. Vol. 14, No. 11,  pp. s-360,  1997.
28. Abbas, R. Browder, N. J. Chow, P.  Odomi, M. and Bramer, S. L. Interspecies Comparison of Cilostazol Pharmacokinetics in Mice, Rats, Dogs, Monkeys, and Humans. Pharm. Res. Vol. 14, No. 11,  pp. s-360,  1997.
29. Moghaddam, A. P., Abbas, R., Fisher, J. W, and Lipscomb, J. C.  The role of mouse intestinal microflora in the metabolism of Trichloroethylene, an In Vitro Study.  Human and Experimental Toxicology.  16, 629-635. 1997.
30. Abbas, R., and Fisher, J. W.  A physiologically based pharmacokinetic model for trichloroethylene and its metabolites, chloral hydrate, trichloroacetate, dichloroacetate, trichloroethanol, and trichloroethanol glucuronide in B6C3F1 mice.  Toxicol. Appl. Pharm.  127, 15-30, 1997.
31. Fu, C. J., Abbas, R. Tata, P. Chow, P. Browder, N. J. and Bramer, S. L. An HPLC method for the analysis of toborinone and four metabolites in human liver microsomal incubation solutions. Pharm. Res. Vol. 14, No. 11,  pp. s-566,  1997. 

32.  Abbas, R. and W. L. Hayton.  A Physiologically Based Pharmacokinetic and Pharmacodynamic Model for Paraoxon in Rainbow Trout.  Toxicol. Appl. Pharmacol., 145, 192-201, 1997.

33. Brashear. W. T., Bishop, C. T., and Abbas, R.  Electrospray analysis of biological samples for trace amounts of trichloroacetic acid, dichloroacetic acid and monochloroacetic acid.  J. of Anal. Tox.  21, 330-334, 1997.
34. Abbas, R., Seckel, C. S. and Fisher, J. W.:  Determination of kinetic rate constants for chloral hydrate, trichloroethanol, trichloroacetate and dichloroacetate: a PBPK model approach. The Toxicologist, vol. 36, No. 1, 164, 1997. 
35. Fisher, J. W , J. D. Pleil, MacMahon, K. L. and Abbas, R.: A Physiologically Based Pharmacokinetic Model for inhalation of trichloroethylene in human volunteers. The Toxicologist, vol. 36, No. 1, 163, 1997.
36. Greenberg, M.S. Abbas, R. and Fisher, J. W: A Physiologically Based Pharmacokinetic Model for inhaled trichloroethylene and its major metabolites in B6C3F1 mice. The Toxicologist, vol. 36, No. 1, 162, 1997.
37. Geiss, K. T., Young, R. S., Randall, G., Kidney, J. K. Channel, S. R. and Abbas, R.:  Induction of Peroxisome Proliferation-Associated genes after administration of Trichloroethylene to Mice. The Toxicologist, vol. 36, No. 1, 1185, 1997.
38. Bishop, C. T., Brashear, W. T., Pollard, D. L., and Abbas, R.: Analysis of Trichloroethylene in Biological Samples. The Toxicologist, vol. 36, No. 1, 1630, 1997.
39. Zhang, H. M, Brashear, W. T., Buttler, G. T., Callaghan, P. Black, R. and Abbas, R. :  An Electron Capture Gas Chromatography Method for Analysis of Dichloroacetic Acid, Trichloroacetic Acid and Trichloroethanol in Biological Matrices. The Toxicologist, vol. 36, No. 1, 1631, 1997.
40. Lipscomb, J.C., Black, R.K., Janicki, T. J., Mahle D. A., Fisher, J. W. and Abbas, R.: Destruction of Cytochrome P450 in Vitro by Trichloroethylene: Loss of CYP3A and CYP1A Activity. The Toxicologist, vol. 36, No. 1, 1610, 1997.
41. Moghaddam, A. P., Abbas, R., Fisher, J. W,  Stavrou, S. and Lipscomb, J. C.  Metabolism of Trichloroethylene and Trichloroacetic Acid by Mouse Gut Microflora, an In Vitro Study.  The Toxicologist, vol. 36, No. 1, 1610, 1997.
42. Abbas, R.,  Seckel, C. S., Kidney, J. K., and  Fisher, J. W. PHARMACOKINETIC ANALYSIS OF CHLORAL HYDRATE AND ITS METABOLISM IN B6C3F1 MICE. Drug Metabolism and Disposition. Vol. 24, No. 12 p 1340-1346. 1996.
43. Moghaddam, A. P., Abbas, R., Fisher, J. W., Stavrou, S., and Lipscomb, J. C.  Formation of dichloroacetic acid by rat and mouse gut microflora, an in vitro study.  Biochem. Biophys. Res. Comm.  228, 639-645, 1996.
44. Abbas, R., Schultz, I. R., Doddapaneni, S. and Hayton, W. L.   Toxicokinetics of Parathion and Paraoxon in Rainbow Trout after Intravascular Administration and Water Exposure.  Toxicol. Appl. Pharmacol.  136, 194-199, 1996.
45. Abbas R., and Hayton W L. Gas Chromatographic Determination of Parathion and paraoxon in fish plasma and tissues.  Journal of Analytical Toxicology, Vol. 20, 151-154, 1996. 
46. Moghaddam, A. P., Abbas, R., Fisher, J. W., Stavrou, S., and Lipscomb, J. C.  Formation of dichloroacetic acid by rat and mouse gut microflora, an in vitro study.  Biochem. Biophys. Res. Comm.  228, 639-645, 1996.
47. Abbas, R., Fisher, J. W.  Black, R. K. and Garrity, B. L.  A Physiologically Based Pharmacokinetic Model to Describe Disposition of Chloral hydrate and Trichloroethanol in Mice.   The International Toxicologist,  33-20. 1995.
48. Hayton, W L, Yu. Z., Abbas, R., Vick, A.  and Doddapaneni, S.  Pharmacokinetics of Acriflavine in Rainbow Trout. The International Toxicologist,  89-16. 1995
49. Abbas, R., Fisher, J. W.,  Black, R. K., Janicki, T. J. and Garrity, B. L.  Disposition of Trichloroethylene and Its Metabolites in B6C3F1 Mice after Oral Administration.   Pharm. Res. Vol. 12, No. 9,  pp. s-338. 1995.
50. Abbas, R. and Hayton, W. L.,  Paraoxon Tissue Distribution and AChE Inhibition in Rainbow Trout.   Pharm. Res. Vol. 10, No. 10, s-365. 1993.
51. Doddapaneni, S.,  Hayton, W. L., Schultz, I. R. and Abbas, R., Tissue  Distribution and Metabolic Disposition of Parathion in Rat. Pharm. Res. Vol. 10, No. 10, s-365. 1993.
52. Doddapaneni, S., Herzberg, U., Schultz, I.R. and Abbas, R. and Hayton, W.L., Parathion and Paraoxon Pharmacokinetics and AChE Inhibition in Rat.  Pharm. Res. Vol. 9, No.10,s 268. 1992.
53. Abbas, R., Schultz, I. R., Doddapaneni, S. and Hayton, W. L., Pharmacokinetics of Paraoxon in Rainbow Trout.  The Toxicologist, 12:1554., 1992.

Conference Papers:

53.  G. Folprecht, J. Tabernero, L. Paz-Ares, J. Baselga, H. Cortes-Funes, E. Casado, F. Rojo, J. Vauthier, Richat Abbas, C. Zacharchuk, C. Koehne.  The irreversible EGFR tyrosine kinase inhibitor EKB-569 in combination with 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) in patients with advanced colorectal cancer (ACC): A phase I/IIa pharmacokinetic and serial skin and tumor pharmacodynamic study.  29th European Society for Medical Oncology (ESMO) Congress. Oct. 29 – Nov. 2, 2004, Vienna, Austria

54.  R Abbas, Y Hijazi, JP Tang, LM Renzetti, A Rames and H Welker.  Safety, Tolerability, and

      Pharmacokinetics of R411, a Dual a4/b1-a4/b7 Integrin Antagonist, after Oral Administration of Single-Ascending Doses in Healthy Male Subjects. Presented at the 2004 Annual Meeting of the American Academy of Allergy, Asthma and Immunology, March 19 - 23, 2004, San Francisco, CA

55.  R Abbas, Y Hijazi, JP Tang, LM Renzetti, A Rames and H Welker^.  Effect of R411, a Dual a4/b1-a4/b7

Integrin Antagonist Being Developed for Asthma, on the Activities of the Major Drug Metabolizing Enzymes After Oral Administration in Healthy Subjects  Presented at the 2004 Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics,  March 24-27, 2004, Maimi Beach, FL

56.  R. Abbas, Y. Hijazi, J. P. Tang, L. M. Renzetti, A. Rames and H. Welker.  Safety, Tolerability and Pharmacokinetics of R411, a Dual a4/b1 and a4/b7 Integrin Antagonist after Multiple-ascending Doses in Healthy Subjects. Preseneted at the 2004 International Conference of the American Thoracic Society.  May 21-26, 2004, Orlando, FL

57.  Richat Abbas, Scott Fettner, Myriam Riek, Sunita Bulsara, Michael Pantze, Marta Hamilton, Paul Frohna, and Ashok Rakhit   A drug-drug interaction study to evaluate the effect of rifampicin on the pharmacokinetics of the EGF receptor tyrosine kinase inhibitor, Tarceva^TM, in healthy subjects.   American Society of Clinical Oncology, May 31 – June 3, 2003 Chicago, IL

58.  C. Kapitza, E. Arbit, R. Abbas, M. Goldberg, M. Hompesch, L. Heinemann, T. Heise, Oral Insulin: Proof of concept in type 2 diabetic patients.  18^th International Diabetes Feration Congress, Aug. 24-29, 2003, Paris, France.

59.  Richat Abbas, Scott Fettner, Myriam Riek, Steve Davis, Marta Hamilton, Paul Frohna, and Ashok Rakhit.  Effect of ketoconazole on the pharmacokinetics of erlotinib (TARCEVA^TM) in healthy adult male subjects. European Association of Clinical Pharmacology and Therapeutics (EACPT), June 24-28, 2003. Istanbul, Turkey

60.  Ashok Rakhit, Scott Fettner, Stephen Davis, Richat Abbas, Flavio De Rosa, Ulrich Brennscheidt, Chis Twelves and Jose Baselga.  Lack of pharmacokinetic interaction between erlotinib, docetaxel and capecitabine in breast cancer patients.  Presented at the 12^th annual Meeting of the Federation of European Cancer Society (ECCO-12), Sept. 21-25, 2003, Copenhagen, Denmark

61.  Richat Abbas, Scott Fettner, Myriam Riek, Stephen Davis, Marta Hamilton, Paul Frohna, Ashok Rakhit.  Clinical pharmacokinetics of  erlotinib in healthy subjects. Presented at the 12^th annual Meeting of the Federation of European Cancer Society (ECCO-12), Sept. 21-25, 2003, Copenhagen, Denmark.

62.  Ehud Arbit MD, Richat Abbas PhD, Steve Dinh PhD and Michael Goldberg MD. The potential clinical implications of the pharmacokinetic profiles of insulin administered by alternate routes. Presented at the 2002 Diabetes Technologies Annual Meeting, Nov. 2002, Atlanta, GA

63.  Richat Abbas, Andrea Leone-Bay, Rajesh Agawal, Shingai Majuru, Paul Rolan, Cyril Clarke, Colin Scott, Ehud Arbit_­, Robert A. Baughman - Oral Insulin: Pharmacokinetics and Pharmacodynamics of Human Insulin Following Oral Administration of an Insulin/Delivery Agent Capsule in Healthy Volunteers – Presentation at the 62nd Annual Meeting American Diabetes Assciation, June 14-16, 2002, San Francisco, CA 

64.  Richat Abbas, Robert A. Baughman, S. De Bruyn, Donald Sarubbi, and Ehud Arbit - Oral Cromolyn: Pharmacokinetics of Cromolyn Sodium Delivered Orally in Healthy Volunteers  - Presentation at the XXI Congress of the European Academy of Allergology and Clinical Immunology, 1-5 June 2002, Naples, Italy.  

65.  Richat Abbas, Rajesh Agarwal, Terry Rivera-Schaub, Andrea Leone-Bay, Kiran Chaudhary, and Robert A. Baughman -  Evaluation of the Effect of Three Different Oral Heparin/SNAC Formulations on Pharmacokinetics (PK) of Heparin Following Oral Administration in Healthy Subjects.  Presented at the Annual Meeting of the American Association of Pharmaceutical Scientists. Nov. 10-14,  2002, Toronto, Canada

66.  Richat Abbas, Robert A. Baughman,  D. de Vries, Steve Dinh and, Ehud Arbit - Pharmacokinetics of Human Insulin Delivered Orally in Healthy Volunteers – Presented at the Diabetes Technologies Meeting, (This was accepted as a best abstract and presented at Diabetes Technologies Meeting).  Nov. 2-3, 2001, San Francisco, CA.

67.  Richat Abbas, A.Chaouki Zerouala, and Robert A. Baughman. Pharmacokinetics (PK) and pharmacodynamics (PD) of SNAd/heparin in  rhesus monkeys. Presented at the 6th ISSX Annual Meeting, October 7-11, 2001, Munich, Germany

68.  Richat Abbas, Alda Pombo-Gentile, and Robert A. Baughman.  Absolute bioavailability of SNAD and Pharmacokinetics of SNAD/heparin in rats.  Presented at the 6th ISSX Annual Meeting, October 7-11, 2001, Munich, Germany.

69.  Richat Abbas, Gregory Osgood, Terry Rivera-Schaub, James C. Kisicki, and Robert A. Baughman.  A Clinical Drug-interaction Study to Evaluate Effect of Antacid Pre-treatment on the Absorption of Heparin and its Delivery Agent, SNAC, Following Oral Administration in Healthy Subjects. Presented at the Annual Meeting of the American Association of Pharmaceutical Scientists. Oct.  2001, Denver, CO.

70.  Richat Abbas, Andrea Leone-Bay, Terry Rivera-Schaub, Shingai Majuru, James C. Kisicki, and Robert A. Baughman.  An Open-label, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of SNAD, an Oral Heparin Delivery Agent, when Administered Orally as SNAD Tablets or Heparin/SNAD Tablets to Healthy Male Volunteers. Presented at the Annual Meeting of the American Association of Pharmaceutical Scientists. Oct.  2001, Denver, CO.

71.  Richat Abbas, Theresa Rivera-Schaub, Igor Rubets, Rajesh Agarwal and Robert A. Baughman.  Clinical Pharmacokinetics and Absolute Bioavailability of the Oral Delivery Agent SNAC when Dosed Orally as SNAC/Heparin to Healthy Volunteers.  Presented at the Pharmaceutical Congress of Americas, March 24-29, 2001, Orlando FL.

72.  Andrea Leone-Bay, Theresa Rivera-Schaub, Shingai Majuru, Richat Abbas, James Kisicki, and Robert A. Baughman.  PHASE I STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF AN ORAL HEPARIN TABLET.  Presented at the American Society of Hematology 2001 Annual Meeting.  December 7 - 11, 2001, Orlando, FL.

73.  Gu, Z., Tata, P. Zhou, D., Abbas, R., Wu, J., Lewis, N. J., and Bramer, S. L.  A sensitive and specific LC-MS/MS method for the analysis of low levels of OPC-29030 and ten metabolites in human plasma and urine.  Presented at the Annual Meeting of the American Association of Pharmaceutical Scientists.  Nov. 15-19.  1998,  San Francisco, CA.

74.  Abbas, R. and W. L. Hayton.  A Physiologically Based Pharmacokinetic and Pharmacodynamic Model for Paraoxon in Rainbow Trout.  Invited speaker at the international symposium, Annual Meeting of the American Chemical Society (ACS) March 28 - April 2, 1998, Dallas, TX.

75.  Abbas, R., Bramer, S. L., Cowart, D., Adeyemo, O. M., Kitani, M., Miyamoto, G., and Browder, N. J.  Interspecies Comparison of TOBORINONE Pharmacokinetics in Rats, Rabbits, Dogs, Monkeys, and Humans.  Presented at the 37^th Annual Meeting of the Society of Toxicology, March 1-5, 1998, Seattle, WA.

76.  Abbas, R., Flockhart, D. A., Thacker, D., Bramer, S. L., Cowart, D.,  and Browder, N. J. In vitro metabolism of toborinone by human liver cytochrome P450 isoforms.  Presented at the 37^th Annual Meeting of the Society of Toxicology, March 1-5, 1998, Seattle, WA.

77.  Abbas, R. Tata, P.  Bramer, S. L.  Li, Y. X. Heitkamp, J.  and Velagaleti, P.  A LC-MS/MS METHOD FOR QUANTITATIVE ANALYSIS OF LOW LEVELS OF R(+) AND S(-) ENANTIOMERS OF OPC-41061 IN HUMAN SERUM.  Presented at the 6^th European International Society for the Study of Xenobiotics Meeting, June 30-July 3, 1997, Gothenburg, Sweden.

78.  Abbas, R. Tata, P.  Bramer, S. L.  Li, Y. X. Heitkamp, J.  and Velagaleti, P.  A SENSITIVE AND SPECIFIC CHIRAL HPLC-MS/MS METHOD FOR QUANTITATIVE ANALYSIS OF LOW LEVELS OF R(+) AND S(-) ENANTIOMERS OF OPC-41061 IN HUMAN SERUM. Presented at the 12^th  Annual Meeting of  American Association of Pharmaceutical Scientists,  Nov. 2-6, 1997. Boston,

79.  Abbas, R. Browder, N. J. Chow, P.  Odomi, M. and Bramer, S. L. Interspecies Comparison of Cilostazol Pharmacokinetics in Mice, Rats, Dogs, Monkeys, and Humans. Presented at the 12^th Annual Meeting of  American Association of Pharmaceutical Scientists,  Nov.  2-6, 1997. Boston,  

80.  Abbas, R., Seckel, C. S. and Fisher, J. W.:  Determination of kinetic rate constants for chloral hydrate, trichloroethanol, trichloroacetate and dichloroacetate: a PBPK model approach. Presented at the 36^th Annual Meeting of the Society of Toxicology, March 9-13, 1997, Cincinnati, OH.

81.  R. Abbas, J. W. Fisher, R. K. Black, T. J. Janicki, and , K. MacMahan. Development of  A Physiologically Based Pharmacokinetic (PBPK) Model for Tricholoroethylene and its Metabolites B6C3F1 Mice. Presented at the  35^th  Annual Meeting of the Society of Toxicology, March 10-14, 1996, Anaheim, CA.

82.  Abbas, R., Fisher, J. W.  Black, R. K. and Garrity, B. L.  A Physiologically Based Pharmacokinetic Model to Describe Disposition of Chloral hydrate and Trichloroethanol in Mice.   Presented at the International Congress of Toxicology – VII, July 2-6, 1995, Seattle, WA.

83.  Abbas, R., Fisher, J. W.,  Black, R. K., Janicki, T. J. and Garrity, B. L.  Disposition of Trichloroethylene and Its Metabolites in B6C3F1 Mice after Oral Administration.   Presented at the 10^th Annual Meeting of  American Association of Pharmaceutical Scientists,  Nov. 5-9, 1995.  Miami, FL.

84.  Abbas, R. and Hayton, W. L.,  In vivo Acetylcholinesterase Inhibition in Rainbow Trout after Water Exposure to Paraoxon.  Presented at the 25th Annual Pharmaceutics Graduate Student Research Meeting, 1993, West Lafayette, Indiana.

85.  Abbas, R. and Hayton, W. L.,  Paraoxon Tissue Distribution and AChE Inhibition in Rainbow Trout.   Presented at the 8^th Annual Meeting of  American Association of Pharmaceutical Scientists, Nov. 14-18, 1993, Lake Vuena Vista, FL.

86.  Abbas, R., Schultz, I. R., Doddapaneni, S. and Hayton, W. L., 1992.  Pharmacokinetics of Paraoxon in Rainbow  Trout.   Presented at the  31^st Annual Meeting of the Society of Toxicology, Feb. 23-28, 1992, Seattle, WA.

PATENTS:

87.  Abbas, Richat,  et al.  “Oral insulin therapy”. United States Patent – 20030198666, U.S. Current Class: 424/452; 424/465; 514/3. U.S. Class at Publication: 424/452; 514/3; 424/465. International Class:  A61K 038/28; A61K 009/48; A61K 009/20

88.  Abbas, Richat, et al. “Formulations for Oral administration of Cromolyn Sodium” US Patenet No. 02789934.3-2123 – US0238247